Table 1.
Patient demographics and baseline characteristics
| Characteristic | Spain n = 119 |
Other Countriesa n = 907 |
|---|---|---|
| Sex, n (%) | ||
| Female | 64 (53.8) | 548 (60.4) |
| Male | 55 (46.2) | 359 (39.6) |
| HAE type, n (%) | ||
| HAE-1 | 114 (95.8) | 838 (92.4) |
| HAE-2 | 5 (4.2) | 69 (7.6) |
| Median (IQR) age at first symptoms, y | 15.0 (5.0–20.0) | 12.0 (5.0–18.0) |
| Median (IQR) age at diagnosis, y | 22.3 (13.6–36.0) | 20.5 (12.6–32.9) |
| Median (IQR) time to diagnosis, yb | 6.4 (1.0–18.3) | 5.4 (0.2–17.0) |
| Median (IQR) age at enrollment, y | 39.3 (27.2–50.4) | 39.0 (27.5–51.8) |
| Median (IQR) age at data extract, y | 45.0 (34.0–56.0) | 44.0 (32.0–57.0) |
| Median (IQR) duration of follow-up in IOS, y | 5.6 (1.2–7.0) | 2.4 (0.4–4.9) |
HAE-1/2 HAE due to C1 inhibitor deficiency, IOS Icatibant Outcome Survey
aAustralia, Austria, Brazil, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Sweden, and the United Kingdom
bDefined as the difference between age at first symptoms and age at diagnosis